ARCHIVES

Six-Year Follow Up Of Phase III Sprycel Trial Demonstrates 71 Percent Overall Survival

This article is from The Cancer Letter archive.

Vol. 35 No. 7 | July 27, 2012

Download PDF Visit The Full Archive

Related Articles

An Angel In heaven – Or How Rejected Grants Do and Don’t Get Reviewed

May 3, 1974

Doxil/Caelyx Survival 3 Weeks Longer Than Topotecan

November 28, 2003

Congress Passes Unprecedented 15% Increase For NIH On Last Day Of Session

October 23, 1998

In Brief: Community ASSN. Developing Clinical Standards Catalogue; Perry Leaves NCI For NIH Position

November 15, 1974

Anti-Nausea Drug Successful In Phase III Trial in Highly Emetogenic Chemotherapy

May 30, 2014

FDA Oncologic Drug Committee Agrees That “Kitty Fight” With NCI Should Be Negotiated

November 28, 1975